Buprenorphine-Naloxone as a Medication to Treat Opioid Use Disorder Among Pregnant Women
Research reaffirms the efficacy, safety, and access of buprenorphine-naloxone as a medication to treat opioid use disorder (MOUD) among women in pregnancy.
What The Data Says
• Findings from a systemic review, meta-analysis, and subgroup analysis reinforce previous support indicating buprenorphine-naloxone during pregnancy has similar pregnancy and neonatal outcomes compared to other forms of treatment such as buprenorphine alone or methadone.
• Results from a subgroup analysis reaffirm that buprenorphine-naloxone treatment has a decreased potential for misuse when compared with that of buprenorphine alone, and in some cases is more available than other forms of treatment.
What Does This Mean?
•Pregnant patients with opioid use disorder and their clinical care team can be reassured that taking buprenorphine-naloxone is relatively safe and effective for both parent and child .
CLICK BELOW TO VIEW INFOGRAPHIC:
Link, Heather Met al. “Buprenorphine-naloxone use in pregnancy: a subgroup analysis of medication to treat opioid use disorder.” American journal of obstetrics & gynecology MFM, vol. 3,5100369. 5 Apr. 2021, doi:10.1016/j.ajogmf.2021.100369 Link, Heather Met al. “Buprenorphine-naloxone use in pregnancy: a systematic review and metaanalysis.” American journal of obstetrics & gynecology MFM vol. 2,3 (2020): 100179. doi:10.1016/j.ajogmf.2020.100179